To investigate non-human leukocyte antigen candidate genes that influence the outcome of human T cell lymphotropic virus (HTLV) type I infection
carriers [HCs] ). However, ∼2%-3% develop ATL, and another 2%-3% develop a disabling chronic inflammatory disease involving the central nervous system (HAM/TSP), eyes, lungs, or skeletal muscles [7] . The lifetime incidence for developing HAM/TSP is only 0.25% in Japan [8] . The factors that cause these different manifestations of HTLV-I infection are not fully understood. However, our previous population association study of 1200 cases of HAM/TSP and 1200 HTLV-I-seropositive HCs revealed several important risk factors for HAM/TSP. One of the major risk factors is the provirus load, as has been reported elsewhere [9] . The median provirus load was 16 times higher in patients with HAM/TSP than in HCs, and a high provirus load was also associated with an increased risk of progression to disease [10] . We next investigated HLA associations and found that the HLA-A*02 and -Cw*08 genes were associated with a lower HTLV-I provirus load and with protection from HAM/TSP, whereas HLA-DRB1*0101 and -B*5401 were associated with susceptibility to HAM/TSP; HLA-B*5401 was also associated with a higher provirus load in patients with HAM/TSP [11, 12] . We further examined the non-HLA host genetic factors that affect the risk of HAM/TSP and reported previously [13] that the tumor necrosis factor promoter Ϫ863 A allele predisposes toward HAM/ TSP, whereas the stromal cell-derived factor-1 +801A 3 untranslated region and interleukin (IL)-15 191 C alleles confer protection. In another study [14] , we reported the association between variation in the HTLV-I tax gene and the risk of HAM/ TSP. The tax subgroup A was more frequently observed in patients with HAM/TSP, and this effect was independent of HLA-A*02. These findings suggest that both host genetic factors and HTLV-I subgroup play a part in determining the risk of HAM/TSP. To investigate further the non-HLA host genetic factors that influence the outcome of HTLV-I infection, we analyzed 6 single-nucleotide polymorphisms (SNPs) in the IL-10 promoter region and quantified the effect of each SNP on the risk of HAM/TSP, because recent studies have revealed a close association between IL-10 promoter polymorphisms and the outcome of certain viral infections, such as Epstein-Barr virus (EBV) [15] , hepatitis B virus (HBV) [16] , hepatitis C virus (HCV) [17] , and HIV-1 [18] , which suggests that particular polymorphisms in the IL-10 promoter contribute to the host immune reaction against viruses.
PATIENTS, MATERIALS, AND METHODS

Study population.
Two hundred eighty patients with HAM/ TSP were compared with 255 randomly selected HCs. All patients and control subjects were Japanese and resided in Kagoshima Prefecture, Japan. The diagnosis of HAM/TSP was made according to the World Health Organization diagnostic criteria [19] . All subjects provided written informed consent.
Detection of SNPs in the IL-10 promoter region. Polymerase chain reaction (PCR)-restriction fragment-length polymorphism analysis was performed for 6 SNPs. Primers and restriction enzymes used in the study are presented in table 1. A genomic PCR was performed with 50 ng of genomic DNA as template, 20 pmol of each primer, 5 mmol/L dNTP, reaction buffer provided by the manufacturer, and 1 U of Takara-Taq DNA polymerase (Takara) in a final volume of 50 mL. Fifteen microliters of the amplified PCR product was then digested for 12 h with the use of each restriction enzyme. Finally, digested PCR products were electrophoresed through a 2% agarose gel and visualized by ethidium bromide.
Provirus load measurement. To examine the HTLV-I provirus load, we performed a quantitative PCR method using an ABI Prism 7700 (PE-Applied Biosystems) with 100 ng of genomic DNA (∼10 4 cells) from peripheral blood mononuclear cell (PBMC) samples, as reported elsewhere [10] . When b-actin was used as an internal control, the amount of HTLV-I provirus DNA was calculated by copy number of HTLV-I (pX) per 1 ϫ . All samples were tested in triplicate. The lower 4 actin/2)] ϫ 10 limit of detection was 1 pX/10 4 PBMCs. Cell line and plasmids. The human T-cell line Jurkat was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. The expression vector pCG-Tax and the control vector pCG-BL were provided by Dr. J. Fujisawa (Kansai Medical University, Osaka, Japan). The pCG-Tax expression vector based on the human cytomegalovirus promoter for HTLV-I tax was constructed by inserting tax cDNA into the XbaI-BamHI site of pCG-BL, as described elsewhere [20] . Human IL-10 promoter fragments (fragment Ϫ890 to +120; GenBank accession number X78437) were amplified by PCR from genomic DNA from 2 patients with HAM/TSP-one Ϫ592 AA homozygote and one CC homozygote-as described elsewhere [21] . The primers used to amplify the IL-10 region were IL-10 -890 (5 -AGC TCG AGA GTT GGC ACT GGT GTA CC-3 ) and IL-10 AS (5 -ACT TCG AAG TTA GGC AGG TTG CCT G-3 ). A promoter fragment that does not contain the Ϫ592 SNP, as well as the neighboring Sp-1 and Ets binding sites (fragment Ϫ571 to +120), was also amplified with the primers IL-10 Ϫ571 (5 -AAC CTC GAG GGA TAT TTA GCC CAC-3 ) and IL-10 AS. The amplified products were subcloned into the pCR-Blunt II-TOPO vector (Invitrogen), and the sequences were confirmed. The correct insertions were subcloned into the XhoI polylinker site of the pGL2 Basic luciferase reporter vector (Promega), and sequences were confirmed again.
Transient transfection and luciferase assay. Five hundred thousand Jurkat cells were cotransfected with 2 mg of a reporter plasmid (IL-10 Ϫ592 A-Luc or IL-10 Ϫ592 C-Luc), together with 0.5 mg of either pCG-Tax or pCG-BL [20] and 300 ng of pRL-TK (Promega), to control transfection efficiency. The results of preliminary studies that measured luciferase activities from cell lysates at 24, 48, and 72 h after transfection indicated that the greatest luciferase activity was at 48 h after transfection. Therefore, after 48 h of cultivation at 37ЊC, cells were harvested, washed with PBS, and lysed in reporter lysis buffer (Promega). Luciferase assays were performed by use of the Dual Luciferase Assay System (Promega) and a TD-20/20 luminometer (Turner Designs). All assays were performed at least 3 times, each in duplicate.
Statistical and logistic-regression analysis. The x 2 test was used to examine associations between HAM/TSP and the IL-10 promoter polymorphism. General linear model (GLM) analysis [22] , which is a general form of multiple regression, was used to identify which factors were predictors of provirus load, in patients with HAM/TSP alone, in HCs alone, or in all subjects in the study. Logistic-regression analysis was used to identify which factors could be used to predict the odds of HAM/ TSP and to fit an equation to estimate the risk in an individual of known genotype. The prevented fraction (Fp) of disease was calculated as described elsewhere [11] .
RESULTS
Association of the IL-10 5592
A allele with a lower risk of HAM/TSP. The median age of patients with HAM/TSP (60.0 years; range, 12-81 years; 69.0% female) was greater than that of HCs (41 years; range, 16-65 years; 57.6% female), and there were more females in the HAM/TSP group and an absence of subjects !16 or 165 years old from the HCs; however, these factors did not affect the frequency of individual HLA alleles (data not shown). In addition, because the prevalence of HAM/ TSP in Kagoshima is !1% among individuals infected with HTLV-I, very few HCs in the present cohort would be expected to develop HAM/TSP. There were no significant differences in the distribution of all genotypes and allele frequencies between 102 patients with HAM/TSP and 102 HCs in 4 SNPs tested (table 2) . The nucleotide at position Ϫ2849 was nonpolymorphic in 102 patients with HAM/TSP and 102 HCs. In contrast, the IL-10 Ϫ592 A/C SNP showed a significant difference in allele frequency. We therefore analyzed further a total of 280 patients with HAM/TSP and 255 HCs (table 2; ; 2 2 x p 8.48 df;
) and identified a significant association between P p .014 possession of an A residue in the IL-10 promoter Ϫ592 A/C SNP and a reduced risk of HAM/TSP. Possession of the IL-10 Ϫ592 A allele was associated with a 12-fold reduction in the odds of developing HAM/TSP ( ; odds ratio [OR], 0.50 P p .011 [95% confidence interval, 0.30-0.86]). Given this OR and the observed frequency of the IL-10 Ϫ592 A allele in Kagoshima, we can estimate the Fp [11] . Here, (SD, ‫)%1.31ע‬ Fp p 44.7% when the prevalence rate of HAM/TSP is 0.01, which indicates that the IL-10 Ϫ592 A allele prevents ∼44.7% (SD, ‫)%1.31ע‬ of potential cases of HAM/TSP in the study population.
Association of the presence of the A allele with a lower provirus load in the whole Kagoshima cohort of HTLV-Iinfected individuals. We next tested the hypothesis that, if a gene is associated with a protection from HAM/TSP, it is also associated with a reduction in provirus load in HCs, given that the risk of developing HAM/TSP is dependent on the provirus load [10] . Table 3 summarizes the HTLV-I provirus load in patients with HAM/TSP and HCs, subdivided according to their IL-10 Ϫ592 A/C genotype. Because histograms of provirus load exhibited right-skewed distributions, the standard statistical technique of logarithmic transformation [22] was also used to mitigate this feature, which resulted in the data being more amenable to statistical analysis by parametric methods. To confirm whether the IL-10 Ϫ592 A/C SNP is a significant predictor of provirus load in the entire cohort, we performed multipleregression analysis (GLMs; see Patients, Materials, and Methods). The results showed that the IL-10 Ϫ592 A/C SNP is a significant predictor of provirus load in the entire cohort (n p 535; , Kruskal-Wallis test; , GLM on the log-P p .004 P ! .01 transformed or -untransformed data). This SNP was also a significant predictor of provirus load in the HC group alone ( ; , Kruskal-Wallis test), but not in the HAM/ n p 255 P p .040 TSP group ( ; , Kruskal-Wallis test). Also, presn p 280 P p .243 ence or absence of the IL-10 Ϫ592 A allele was a significant predictor of the provirus load in the entire cohort ( ; n p 535 , Mann-Whitney U test;
, GLM), although this P p .001 P ! .005 relationship was only marginally significant in the HC group ( ; ; Mann-Whitney U test; , GLM). n p 255 P p .103 P ! .13 These analyses indicate that the IL-10 Ϫ592 A/C SNP was a significant predictor of the provirus load and that the presence of A allele was associated with a lower provirus load in the whole Kagoshima cohort of HTLV-I-infected individuals (table 3) . IL-10 5592 A/C SNP-significant predictor of HAM/TSP even after accounting for provirus load or HLA-A*02. As was already mentioned, there was a significant association between the odds of developing HAM/TSP and the IL-10 Ϫ592 A/C SNP genotype according to the results of single-factor x 2 analysis at both the allele and the genotype level. To confirm whether the IL-10 Ϫ592 A/C SNP genotype remains a significant predictor of HAM/TSP even after taking into account the other significant predictors identified by our previous analyses, such as provirus load and HLA-A*02, we performed logistic-regression analysis. As a result, in logistic-regression analysis that included HTLV-I provirus load and IL-10 Ϫ592 A/C SNP genotype treated as a 3-level factor (i.e., AA vs. AC vs. CC), the IL-10 Ϫ592 A/C SNP remained significant as a predictor of HAM/TSP ( ). We can calculate the risk for HAM/TSP P p .043 by ln(odds of HAM/ (if AC)-0.0235 TSP) p Ϫ4.1212-0.5668 (if (pX/10 4 PBMCs). When we treated the CC) + 2.0764 ϫ log 10 IL-10 Ϫ592 A/C SNP genotype as a 2-level factor, inclusion of the absence or presence of the A allele was not significant when log 10 (pX/10 4 PBMCs) was included (P p .399). However, the inclusion of the absence or presence of C was significant when log 10 (pX/10 4 PBMCs) was included (P p .047). Therefore, we conclude that the IL-10 Ϫ592 A/C SNP genotype has predictive power for HAM/TSP even after we accounted for the HTLV-I provirus load. Next, to test whether the IL-10 Ϫ592 A/C SNP genotype remains a predictor of HAM/TSP even after we accounted for HLA-A*02, we further performed the logisticregression analysis using samples that are available on both IL-10 Ϫ592 A/C SNP and HLA-A*02 ( ). In logisticn p 402 regression analysis that included the HLA-A*02 and IL-10 Ϫ592 A/C SNP genotype, both HLA-A*02 ( ) and IL-10 P p .001 Ϫ592 A/C SNP ( ) remained significant as predictors P p . A/C SNP (Ϫ572 luc) sites. Gray bars, Luc activity of each reporter plasmid with control vector pCG-BL. Black bars, Luc activity of each reporter plasmid with Tax-expressing vector pCG-Tax. The activities are given relative to the activity of each reporter plasmid with control vector pCG-BL, which was defined as 1. The from 3 independent experiments is shown. The basal luciferase activity with pCG-BL was not different mean ‫ע‬ SD between Ϫ890 A-luc and Ϫ890 C-luc. The difference of luciferase activity with pCG-Tax between Ϫ890 A-luc and Ϫ890 C-luc was statistically significant ( , Mann-Whitney U test). CRE, cyclic AMP response element; GM-CSF, granulocyte macrophage colony-stimulating factor; GRE, glu-P ! .01 cocorticoid response element; STAT, signal transducer and activator of transcription.
the residue at position Ϫ592, which allowed us to estimate the functional differences associated with the Ϫ592 A or C residues alone. The results of the experiments showed that the functional differences were associated with the Ϫ592 A or C residues alone on HTLV-I Tax-mediated IL-10 promoter activity. These results showed that the ectopic expression of the Tax protein in Jurkat T cells increased IL-10 promoter activity by ∼3 times with the A construct and 6 times with the C construct, compared with HCs ( , Mann-Whitney U test) (figure 1). In contrast, the P ! .01 promoter fragment (fragment Ϫ571 to +120), which does not contain Ϫ592 SNP, as well as the neighboring Sp-1 and Ets binding site, was not transactivated by Tax. The basal luciferase activity without the transfecting Tax-expression vector (i.e., with transfecting empty vector, pCG-BL) did not differ between the A and C constructs. These results indicated that Tax directly transactivates the IL-10 promoter and that the C allele is more effective for Tax-mediated transcription than the A allele.
DISCUSSION
IL-10 is an important immunoregulatory cytokine that is involved in inflammatory responses, autoimmune diseases, and the response to infectious agents [23] . Although IL-10 has been reported to suppress the synthesis of proinflammatory cytokines from T cells and monocytes/macrophages, animal models have suggested that the overexpression of IL-10 in vivo can cause organ-specific autoimmune diseases, such as Sjögren syndrome [24] and type 1 diabetes [25] . Therefore, IL-10 is not regarded simply as an immunoinhibitory cytokine but also as a powerful immunostimulatory cytokine. Because transgenic mice containing the HTLV-I tax gene under the control of the viral long-terminal repeat (LTR) have previously been shown to develop an exocrinopathy involving the salivary and lachrymal glands that resembles Sjögren syndrome [26] , which is frequently observed in patients with HAM/TSP [27] , and be-cause IL-10 mRNA expression was induced by HTLV-I Tax in both transiently and stably transfected Jurkat cells [28] , it is likely that Tax directly transactivates the IL-10 promoter. The resulting overexpression of Tax in vivo may cause a Sjögren-like syndrome via an IL-10-mediated mechanism.
The implication of a heritable genetic basis for IL-10 production is supported by the concordance of IL-10 production in monozygotic twins, which suggests that genetic polymorphism could account for up to 75% of the observed variation in IL-10 production [29] . As was already mentioned, several studies have shown an association between particular polymorphisms in the human IL-10 promoter region and the outcome of certain viral infections, such as EBV [15] , HBV [16] , HCV [17] , and HIV-1 [18] . In view of the immunomodulatory and anti-inflammatory effects of IL-10, we initially hypothesized that genetically determined lower production of IL-10 (associated with the allele Ϫ592 A) might influence disease susceptibility to HAM/TSP. This is the case for HIV-1 infection, because individuals with the IL-10 Ϫ592 AA genotype have been reported to be at higher risk of HIV-1 infection and rapid progression to AIDS [18] . In contrast, the present data show that, in HTLV-I infection, possession of the IL-10 Ϫ592 A allele prevented ∼44.7% (SD, ‫)%1.31ע‬ of potential cases of HAM/ TSP and was also a significant predictor for a lower provirus load in the entire cohort.
The Ϫ592 A/C SNP is located between the Sp1 and Ets binding site within the region between Ϫ652 and Ϫ571 nt that is necessary for IL-10 transcription [21] . It is of interest that previous reports have indicated that Tax transactivates the parathyroid hormone-related protein promoter by forming a ternary complex between Tax, Ets, and Sp-1, which acts on the promoter Sp-1 and Ets binding sites [30] . Another report showed that the HTLV-I LTR also contains a motif related to the Ets-binding sequence, named TRE-2S [31] . More important, 1 copy of the cyclic AMP response element (CRE)-like 21-bp sequence and TRE-2S in the HTLV-I LTR, contributes to the transactivation of viral gene via a ternary complex formed between Tax, Gli2 (TRE-S binding Gli oncogene family protein), and CRE-binding protein [32] . These findings suggest that a common mechanism of the HTLV-I Tax-mediated transactivation of the promoter of target genes ternary complexes formed with 2 different transcription factors. Furthermore, the results also suggest that the IL-10 promoter Ϫ592 A/C SNP, which lies between the Sp-1 and Ets binding sites, affects Taxmediated transcription. Indeed, our cotransfection study using a Tax-expressing vector and Jurkat cells demonstrated that a IL-10 Ϫ592 luciferase vector carrying the high producer allele (C) showed higher Tax-mediated transcription than that of low producer allele (A), whereas a promoter fragment (fragment Ϫ571 to +120) that does not contain Ϫ592 SNP, as well as the neighboring Sp-1 and Ets binding site, was not transactivated by Tax. These findings suggested that HTLV-I Tax directly transactivates the IL-10 promoter and that the Ϫ592 A/C SNP affects Tax-induced transcription-that is, that the C allele is more effective than the A allele in mediating the Tax-induced transcription of IL-10. In future studies, it may be interesting to test whether Tax, Ets, and Sp-1 form a ternary complex on the IL-10 promoter and whether the Ϫ592 SNP affects this complex formation.
Among 190 non-HLA candidate gene loci that we have so far examined, the IL-10 Ϫ592 A/C SNP is the only non-HLA candidate gene locus associated with a significant reduction in both the provirus load and the risk of HAM/TSP. This observation is exactly analogous to the argument that we previously reported for HLA-A*02 and -Cw*08, where, in each case, possession of the allele was associated with both a significant reduction in provirus load in the HCs and a significant reduction in the risk of HAM/TSP [11, 12] . Thus, one possible mechanism for the observed IL-10 promoter effect is that increased the production of IL-10 reduces the efficiency of immune surveillance of HTLV-I infection-for example, by reducing the number or the activity of HTLV-I-specific cytotoxic T lymphocytes. However, the IL-10 promoter genotype remained a significant predictor of the risk of HAM/TSP even after taking the provirus load into account. This observation suggests that IL-10 increases the risk of HAM/TSP by another mechanism in addition to an apparent effect on provirus load.
In conclusion, we report that the IL-10 Ϫ592 A allele, which is associated with lower HTLV-I Tax-mediated transcriptional activity, influences both the provirus load in HTLV-I-infected individuals and the susceptibility to HAM/TSP in the Kagoshima cohort. This effect remains significant even after taking into account the other 2 known major predictors of HAM/TSP risk in this cohort-provirus load and HLA-A*02 genotypewhich suggests a powerful argument in favor of a real physiological effect of this polymorphism. Further functional studies to clarify the role of IL-10 in HTLV-I infection may reveal immunotherapeutic strategies that would retard the development of HAM/TSP.
